1. Home
  2. BAP vs WAT Comparison

BAP vs WAT Comparison

Compare BAP & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credicorp Ltd.

BAP

Credicorp Ltd.

HOLD

Current Price

$272.14

Market Cap

21.1B

Sector

Finance

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$394.93

Market Cap

17.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAP
WAT
Founded
1889
1958
Country
Peru
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
17.4B
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
BAP
WAT
Price
$272.14
$394.93
Analyst Decision
Buy
Buy
Analyst Count
6
14
Target Price
$260.17
$382.14
AVG Volume (30 Days)
316.1K
531.7K
Earning Date
11-13-2025
11-04-2025
Dividend Yield
4.04%
N/A
EPS Growth
24.08
3.82
EPS
23.44
10.88
Revenue
$5,896,627,147.00
$3,105,638,000.00
Revenue This Year
$24.38
$7.96
Revenue Next Year
$7.81
$6.32
P/E Ratio
$11.62
$36.30
Revenue Growth
19.24
6.90
52 Week Low
$165.51
$275.05
52 Week High
$280.88
$423.56

Technical Indicators

Market Signals
Indicator
BAP
WAT
Relative Strength Index (RSI) 63.51 61.33
Support Level $240.00 $386.09
Resistance Level $258.10 $403.80
Average True Range (ATR) 7.28 9.63
MACD 2.51 -1.66
Stochastic Oscillator 80.77 53.55

Price Performance

Historical Comparison
BAP
WAT

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: